Nuvalent | Investor Presentation Deck

Slide schematic 5/5

list 1/1 paragraph 1/1 source-note 1/1 title 2/2

Components 5

bullet paragraph source-note action-title headline

Tools 1

3L+ column: No clear SOC, ~25-50% compound mutations, >60% CNS disease. 2L column: Current SOC Lorlatinib, ~50% single mutations, >60% CNS disease. 1L column: Current SOC Alectinib, ALK ~3-5% of NSCLC, ~30-40% CNS disease.

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.